EPS for Catalyst Biosciences, Inc. (CBIO) Expected At $-1.30 as of May, 10

April 17, 2018 - By Jenna Rose

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Corporate Logo

Earnings report for Catalyst Biosciences, Inc. (NASDAQ:CBIO) is awaited On May, 10., Zacks reports. Analysts forecast $-1.30 earnings per share, which is $3.27 up or 71.55 % from 2017’s $-4.57 earnings per share. After $-0.96 EPS report last quarter, Wall Street now predicts 35.42 % negative EPS growth of Catalyst Biosciences, Inc.. Its shares touched $24.87 on during the last trading session after 1.47% change.Catalyst Biosciences, Inc. has volume of 165,301 shares. Since April 17, 2017 CBIO has risen 405.24% and is uptrending. The stock outperformed the S&P500 by 393.69%.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications.The company has $295.79 million market cap. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors.Currently it has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.